162012-72-8

Basic information

• Product Name: 6-METHOXY-7-HYDROXYQUINAZOLIN-4-ONE
• Synonyms: 6-METHOXY-7-HYDROXYQUINAZOLIN-4-ONE;6-Methoxy-7-Hydroxyquinazoline-4-One;6-methoxy-7-hydydroxyquinazoline-4-one;7-Hydroxy-6-Methoxy-3,4-d...;7-Hydroxy-6-Methoxy-3,4-dihydroquinazolin-4-one;7-hydroxy-6-methoxyquinazolin-4(1H)-one;7-hydroxy-6-methoxy-4(3H)-Quinazolinone;7-Hydroxy-6-methoxy-3H-quinazolin-4-one
• CAS NO: 162012-72-8
• Molecular Formula: C₉H₈N₂O₃
• Molecular Weight: 192.17
• Mol File: 162012-72-8.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 420.0±55.0 °C(Predicted)
• Appearance: /
• Density: 1.47±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly, Heated), Methanol (Slightly, Heated)
• PKA: 8.07±0.20(Predicted)
• CAS DataBase Reference: 6-METHOXY-7-HYDROXYQUINAZOLIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHOXY-7-HYDROXYQUINAZOLIN-4-ONE(162012-72-8)
• EPA Substance Registry System: 6-METHOXY-7-HYDROXYQUINAZOLIN-4-ONE(162012-72-8)

Safety Data

• Hazardous Substances Data: 162012-72-8(Hazardous Substances Data)

Usage

Uses

7-Hydroxy-6-methoxy-3,4-dihydroquinazolin-4-one is a potential 2-arylbenzothiazoles based kinase inhibitor.

Upstream product

• 848092-84-2 methyl 2-amino-4-hydroxy-5-methoxybenzoate 
• 77287-34-4 formamide 
• 16712-16-6 ammonium formate 
• 61032-42-6 methyl 2-amino-4-(benzyloxy)-5-methoxybenzoate 
• 61032-41-5 methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate 
• 56441-97-5 methyl 4-(benzyloxy)-3-methoxybenzoate 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 916606-81-0 7-hydroxy-6-methoxyquinazoline 
• 741276-49-3 C₁₆H₁₄N₂O₂ 
• 179688-01-8 7-(benzyloxy)-6-methoxyquinazolin-4(3H)-one 

Downstream Products

• 179688-02-9 7-acetoxy-6-methoxy-3,4-dihydroquinazolin-4-one 
• 1622396-50-2 C₃₂H₃₈N₆O₅ 
• 1622396-69-3 C₂₁H₂₂ClN₃O₅ 
• 1622396-70-6 C₂₆H₂₆ClN₅O₇ 
• 1622396-71-7 C₂₄H₂₂ClN₅O₇ 
• 1622343-29-6 C₃₁H₃₃ClN₆O₇ 
• 1622396-72-8 C₂₉H₂₈ClFN₄O₆ 
• 1622396-73-9 C₂₇H₂₄ClFN₄O₆ 
• 1622343-45-6 C₃₄H₃₅ClFN₅O₆ 
• 1622396-81-9 C₂₁H₂₂ClN₃O₅ 
• 1622343-33-2 C₂₉H₂₈ClFN₄O₆ 
• 1622343-17-2 C₂₆H₂₆ClN₅O₇ 
• 263400-68-6 4-chloro-6-methoxy-quinazolin-7-ol 
• 199327-59-8 4-chloro-7-methoxy-6-(3-morpholinopropoxy)quinazoline 

Relevant articles and documents

Gefitinib and its derivatives of the new method for microwave synthesis

The invention discloses a new method for performing microwave synthesis on gefitinib and a derivative thereof. The method comprises the following steps of: at first, synthesizing 6-methoxyl-7-hydroxyl quinazoline-4-one from 2-iodo (bromo)-4-methoxyl-5-hydroxyl cyanophenyl used as an initial raw material and formamidine hydrochloride in a microwave mode; then performing reaction with 4-(3-bromo propyl) morpholine to introduce an alkyl side chain so as to obtain 7-methoxyl-6-[3-(4-morpholinyl) propoxy] quinazoline-4-ketone; in the presence of a catalyst, performing reaction on the obtained product and a chlorination reagent to obtain 4-chloro-7-methoxyl-6-[3-(4-morpholinyl) propoxy] quinazoline; finally, performing reaction on 4-chloro-7-methoxyl-6-[3-(4-morpholinyl) propoxy] quinazoline and 3-chloro-4-fluoroaniline to obtain a final product 4-(3-chloro-4-fluoroanilino)-7-methoxyl-6-(3-morpholinyl propoxy) quinazoline (gefitinib). The whole route steps are simplified into four steps, the yield is high, the method is convenient to carry out, the dangerousness is low, and the application of high-pollution reagents is reduced; moreover, the whole route is high in economy and suitable for industrial production, and the product cost is reduced. The reaction formula is as shown in the specification.

THERAPEUTIC COMPOUNDS AND USES THEREOF

Described herein are compounds of Formula (I) or Formula (VI), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I) or Formula (VI) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided.

Substituted 2-arylbenzothiazoles as kinase inhibitors: Hit-to-lead optimization

Based on an (aminoaryl)benzothiazole quinazoline hit structure for kinase inhibition, a systematic optimization program resulted in a lead structure allowing for inhibitory activities in cellular phosphorylation assays in the low nanomolar range.